Leading Autism Care Provider Invites MPs to Meet Residents and Staff for World Autism Awareness Day
LONDON, March 27 /PRNewswire/ -- Brookdale Care, the independent provider of residential care services for people living with Autism and other Autistic Spectrum Disorders (ASD), is inviting MPs and care commissioners to spend a day with residents and staff at four of its residential locations ...Twins Pitcher Glen Perkins Kicks Off 7th Anniversary of Fitness Program in MPS
MINNEAPOLIS, Jan. 16 /PRNewswire-USNewswire/ -- More than 15,000 students at 53 Minneapolis Public Schools (MPS) sites will participate in the Presidential Active Lifestyle Award (PALA) program sponsored by the General Mills Foundation, AchieveMpls and MPS. Richard Green Central Park Communit...Under-Elevens Hurtle Towards Obesity, British MPs Call for Action
A group of powerful British MPs, members of the Committee of Public Accounts, has come out strongly against officials given the charge of tackling child obesity//. Levels of obesity in children aged two to 10 years have risen from 9.9 percent to 13.4 percent between 1995 and 2004, according to ...Indian MPs to Attend AIDS Conference in Lahore
Ten Indian parliamentarians will attend a two-day conference on AIDS in Lahore to discuss// the role of people's elected representatives in combating the disease. The Parliamentarians for Global Action (PGA), a worldwide network of individual parliamentarians, in collaboration with the provinc...A Wake-up Call by MPs to Ensure Timely Care to Stroke Victims
A recent report has placed on record the inadequate resources provided by the government to help the hundreds of stroke victims in England. This sub-standard quality// of treatment has left many stroke victims invalid. According to NHS figures, nearly 500 deaths can be averted with timely treatment...UK MPs Vote In Favor Of Public Smoking Ban
Following the overwhelming response of MPs in favor of the proposed smoking ban in public places, it is expected that the new smoking ban law would be imposed by the summer of next year in the UK. // A 200-margin victory of 384 Vs 184 has been achieved when the issue of smoking ban extension...Doctors Ask MPs To Protect Human Rights By Banning Smoking In Enclosed Public Spaces
The BMA Chairman, Dr James Johnson has urged all MPs in England to exercise their free vote to ensure that smoking was banned in all enclosed public spaces. In a letter to all MP's, Dr Johnson said, “A partial ban on smoking in public place// disregards the human rights of workers and customer...British MPs Say Prostate Cancer Receives Low Priority in the NHS
The House of Commons public accounts committee (PAC) in the UK has severely criticized the NHS for failing to supply accurate information about cancer to patients. The committee also castigated the NHS for according a low priority to prostate cancer as compared to some other cancers. // The repo...BioMarin Announces Second Quarter 2009 Financial Results
...tudy, initiated the Phase I/II study for GALNS for mps IVA and recently completed enrollment for this stu...trial are expected in mid-2010. GALNS for mps IVA: BioMarin initiated the Phase I/II trial in m... 1H10: Results from Phase I/II trial for GALNS for mps IVA Mid-2010: Results from PEG-PAL Phase II t...Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release...BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
...me replacement therapies, one for the treatment of mps I and one for the treatment of mps VI. Naglazyme(R) (galsulfase) for mps VI is wholly developed and commercialized by BioMa...Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
...and is produced by recombinant DNA technology in a human cell line. ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, mps II.) ELAPRASE has been shown to improve walking capacity in these patients. Safety Considerations Some patients in the clinical trials experienced...BioMarin Announces FDA Approval for Kuvan
.... BioMarin will offer support to PKU patients through its BioMarin Patient and Physician Support (BPPS) program. BPPS currently provides support for mps VI patients treated with Naglazyme, and a similar support program will be available for PKU patients. For more information about the BioMarin Patient ...One Shot of Gene Therapy Spreads Through Brain in Animal Study
...ent Cassia N. Cearley performed the study in mice specially bred to have the neurogenetic disease mucopolysaccharidosis type VII (MPS VII). In people, mps VII, also called Sly syndrome, is a rare, multisystem disease causing mental retardation and death in childhood or early adulthood. Sly syndrome is o...BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
... AnGes to bring the first drug treatment option to mps VI patients in Japan," said Stephen Aselage, Senio...C) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...Health, Labour and Welfare (MHLW) in Japan. About mps VI ...BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
NOVATO, Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome. BioMarin plans to initiate a Phase 1/2...Kuvan Receives Priority Review Status From Health Canada
...ment for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Jefferies Healthcare Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Goldman Sachs Healthcare Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Deutsche Bank Health Care Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin to Present at the Baird Growth Stock Conference
...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...BioMarin Announces First Quarter 2009 Financial Results
...g programs including PEG-PAL for PKU and GALNS for mps IVA. We are strategically developing earlier stag...ial are expected in mid-2010. GALNS for mps IVA: BioMarin initiated the Phase I/II trial in m... 1H10: Results from Phase I/II trial for GALNS for mps IVA Mid-2010: Results from PEG-PAL Phase I...Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
...ilize MPS' Equity by Design (TM) product. mps will evaluate all equipment designs for fit and pu...lated to design, constructability and cleanliness. mps will also provide a final report, identifying budg...id, "Equity by Design(TM) is a program whereby mps provides certain Technical Advisory Services in wh...BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
...me replacement therapies, one for the treatment of mps I and one for the treatment of mps VI. Naglazyme(R) (galsulfase) for mps VI is wholly developed and commercialized by BioMa...